報價延遲最少15分鐘:2025/06/03 19:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.85/-2.91
|
|
企業價值
105.98M
|
| 資產負債 |
|
每股賬面淨值
5.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
52.30M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 19:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others. |